Novartis AG (NVS) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Novartis AG stock price
Novartis AG latest news:
Reps. Cummings, Welch to launch investigation into multiple sclerosis drug prices
Rep. Elijah Cummings (D-Md.) and Rep. Peter Welch (D-Vt.) said Thursday morning that they are launching an investigation into multiple sclerosis drug prices, and have sent letters to seven pharmaceutical companies about their pricing strategies. Letters were sent to Bayer AG , Biogen Inc. , Merck & Co.'s EMD Serono, Novartis AG , Sanofi SA , Teva Pharmaceutical Industries Ltd. and Roche Holding AG . Biogen shares declined 2.9% in heavy midday trade and Teva shares declined 1.1% in moderate trade. The lawmakers asked for information to evaluate multiple sclerosis drugs' "substantial price increases, including information about corporate profits and expenses and documents concerning pricing strategies, patient assistance programs, and drug distribution systems," and requested a response by the end of the month. The average price of a multiple sclerosis disease-modifying therapy rose from $16,000 in 2004 to about $84,000 in 2017, according to the National Multiple Sclerosis Society (the numbers refer to average wholesale price, which does not reflect often-substantial discounts and rebates). Prices for drugs sold by the seven drugmakers have increased by as much as 1,002% since 2012, according to information from the National Multiple Sclerosis Society cited by the two representatives. The lawmakers said that their letter referred to an American Academy of Neurology study that found "some drug companies appear to be increasing their prices and setting new, higher prices in lockstep in competitors," which may reflect a phenomenon called "shadow pricing" in which companies respond to eachothers' price increases. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
United Therapeutics Corp. stock surges 9% on report of possible bids for company
United Therapeutics Corp. shares surged 8.7% premarket on Friday after a news report suggested that major pharmaceutical companies were weighing a bid for it. The Evening Standard report said that Gilead Sciences Inc. is considered the frontrunner, while GlaxoSmithKline PLC and Novartis AG are also possible contenders. Glaxo and United Therapeutics declined to comment to the Evening Standard. United Therapeutic, which was founded by Martine Rothblatt, a co-founder of Sirius XM , currently has five products on the market, four of which treat pulmonary arterial hypertension; the fifth is intended for pediatric cancer patients. United Therapeutics shares have dropped 11.5% year-to-date, compared with a 10.4% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
U.S. jury sides with Amphastar over Momenta in drug patent trial
Amphastar Pharmaceuticals Inc(AMPH) on Friday won a trial in a lawsuit claiming that the drugmaker through its production of a generic version of the blood-thinner Lovenox infringed a patent held by Momenta Pharmaceuticals Inc. The verdict by a federal jury in Boston came in a long-running lawsuit pursued by Cambridge, Massachusetts-based biopharmaceutical company Momenta and its partner, Novartis AG...
UPDATE 1-Novartis sees Alcon recovery opening door to spin-off IPO
* Sandoz hit again by U.S. price pressure
(Adds comment from CEO, analyst, details throughout)
Novartis net profit grows 10 percent in Q2, but sales dip
Swiss pharmaceutical company Novartis says its net profit rose 10 percent in the second quarter, helped by gains from divestments.
Novel leukemia treatment could be 1st US gene therapy
Cancer experts who advise government regulators are reviewing what could be the first gene therapy approved in the U.S. The Food and Drug Administration panel is holding a hearing Wednesday to discuss the treatment developed by the University of Pennsylvania and Novartis Corp.
Novartis gets FDA panel recommendation for leukemia drug approval
U.S. shares of Novartis AG rose in the extended session Wednesday after a Food and Drug Administration advisory panel unanimously recommended that the agency approve one of its cancer drugs. U.S.-traded Novartis shares rose 1.7% to $84.60 after hours. The company said the FDA's Oncologic Drugs Advisory Committee voted 10 to 0 in favor of approving Novartis's drug tisagenlecleucel for the treatment of children and young adults with B-cell acute lymphoblastic leukemia, a type of blood cancer. The FDA is not obligated to follow the recommendations of its advisory panels but generally does.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Pioneering cancer gene therapy by Novartis backed by U.S. panel
Novartis AG's pioneering cancer drug won the backing of a federal advisory panel on Wednesday, paving the way for the first gene therapy to be approved in the United States.
BRIEF-Novartis says FDA accepts Sandoz regulatory submission for generic version of Advair Diskus
* FDA accepts Sandoz regulatory submission for a generic
version of Advair Diskus
Google bets on European biotech drugs, backs new fund
LONDON, June 15 (Reuters) - Google is betting on the
potential of European biotech companies to deliver life-changing
drugs by investing alongside Swiss company Novartis in
a new $300 million fund run by leading life sciences investment
BRIEF-Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer
Bristol-myers Squibb Co(BMY). * Bristol-Myers Squibb(BMY) announces new collaboration to evaluate combination therapy in colorectal cancer. * Entered into a clinical research collaboration with Novartis Source text for Eikon: Further company coverage:
Novartis CEO sees no need for big takeover
Novartis does not need a big acquisition to kick-start growth, Chief Executive Joe Jimenez told investors on Wednesday, playing down suggestions he could use proceeds from a slew of asset sales for a significant takeover.
Novartis warns of U.S. price pressure on Sandoz generics
ZURICH (Reuters) - Novartis warned on Wednesday that price pressure on its generics drugs in the United States has intensified in the second quarter, cutting into its Sandoz division's sales growth in the world's largest healthcare market.
UPDATE 1-Novartis warns of U.S. price pressure on Sandoz generics
ZURICH, May 31 (Reuters) - Novartis warned on
Wednesday that price pressure on its generics drugs in the
United States has intensified in the second quarter, cutting
into its Sandoz division's sales growth in the world's largest
Novo Nordisk A/SNVO
NQ Mobile Inc.NQ
Nu Skin EnterprisesNUS
Nustar Energy L.P.NS